GradedHealth

Low FODMAP Diet

Last reviewed October 2026 · Based on 17 studies

Bottom line

The low FODMAP diet eases irritable bowel syndrome symptoms, belly pain and bloating more than a habitual diet in pooled trials. Long-term benefit is less clear, traditional dietary advice did about as well in one trial, and the diet restricts fibre-rich foods.

What it helps with

  • Eases IBS symptoms — Benefit, evidence grade B (Moderate). Network meta-analyses of 13 and 28 RCTs favour the diet over habitual eating; downgraded for risk of bias because diet trials cannot be fully blinded.
  • Relieves belly pain in IBS — Benefit, evidence grade B (Moderate). Network meta-analysis and a pooled efficacy analysis favour the diet; downgraded for risk of bias from unblinded diet trials.
  • Reduces bloating — Benefit, evidence grade B (Moderate). Two network meta-analyses agree that the diet beats habitual eating and standard advice for bloating; downgraded for risk of bias.
  • Changes bowel habits — No effect, evidence grade B (Moderate). Network meta-analysis of 23 trials found no dietary intervention superior to control for bowel habit; downgraded for risk of bias.
  • Keeps IBS symptoms better over time — Mixed results, evidence grade C (Limited). A 2017 trial and a 2021 trial show lasting benefit with reintroduction, while a 12-month trial found the standard diet's benefit faded; small trials, downgraded for inconsistency and small samples.
  • Cuts fibre intake — Harm, evidence grade C (Limited). One 50-person trial found lower fibre on the diet; a 2022 trial found no significant difference in overall nutrient intake; small trials, downgraded.
  • Changes gut bacteria diversity — No effect, evidence grade C (Limited). Meta-analysis of 9 small trials found no clear diversity change; a consistent drop in Bifidobacteria is a biomarker; downgraded for small trials.
  • Works better than other diets — Mixed results, evidence grade C (Limited). The 2022 network meta-analysis ranks the diet first, but a head-to-head trial found traditional advice about as effective; downgraded for inconsistency and small trials.

What it is

A diet that limits fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs), which are fermentable sugars and related carbohydrates [1]. It is used mainly for irritable bowel syndrome (IBS).

What the research says

A 2025 network meta-analysis of 28 trials (2,338 people) found the diet beat a habitual diet for global IBS symptoms (RR 0.51), abdominal pain (RR 0.61) and bloating (RR 0.55) [2]. A 2022 network meta-analysis of 13 trials (944 people) ranked it first for global symptoms against a habitual diet (RR 0.67) [3]. A 2024 meta-analysis of efficacy studies found benefit for abdominal pain (SMD 0.35), with real-world studies also improving [4].

In a 3-week crossover trial of 30 people, symptom scores were about half as high on the low FODMAP diet as on a typical diet (22.8 against 44.9 mm) [1]. A 2022 trial found traditional dietary advice produced a similar response rate (42%) to the low FODMAP diet (55%), not a significant difference [5]. In a three-arm 2024 trial, 76% on the low FODMAP diet plus advice responded, against 58% on medication [6].

Bowel habit did not change more than with control diets in the 2025 network meta-analysis [2]. A 2017 trial found symptom scores stayed lower for 6 months after reintroducing foods [7]. A 12-month follow-up found the standard diet's benefit faded, while a personalised diet kept its improvement [8]. Across nine trials, the diet consistently lowered Bifidobacteria, with no clear change in overall diversity [9].

Doses used in studies

Trials compared about 4 grams of FODMAPs a day with about 23 grams a day on a moderate diet, in 7-day periods [10]. One trial aimed for under 0.5 grams per meal over 21 days [1]. A 2026 trial used a 6-week diet period and followed people for 12 months [8]. These are study settings, not recommendations.

Safety and interactions

Side effects: the 2024 three-arm trial reported no serious adverse events, and two people in each diet group stopped because of adverse events [6]. Fibre intake fell from 33 to 21 grams a day in a 2017 trial [7]. A 2022 trial found no significant difference in overall micronutrient or macronutrient intake between diets [5].

No data were found in the studies reviewed on upper intake limits, toxic doses, medicine interactions, or use in pregnancy and breastfeeding. In quiescent inflammatory bowel disease, a 4-week low FODMAP diet improved gut symptoms but did not change inflammation markers [11], and a 2025 review concluded it is not an IBD treatment [12]. People with IBD, pregnancy or nutritional concerns should ask a doctor or dietitian before starting.

Caveats and open questions

In the 2025 network meta-analysis, most comparisons were rated low or very low confidence; the direct low FODMAP vs habitual diet comparison was rated moderate [2]. Diet trials are hard to blind, and most were run in secondary or tertiary care [3]. Traditional advice did about as well in one head-to-head trial [5]. The 12-month personalised-diet trial is hypothesis-generating, and its authors include people with ties to the company that developed the approach [8]. A pilot 2025 trial suggested that fructans and galacto-oligosaccharides may be the main triggers, with a larger trial still needed [13].

References

  1. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.. Gastroenterology, 2014.
  2. Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis.. Lancet Gastroenterol Hepatol, 2025.
  3. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.. Gut, 2022.
  4. The efficacy and real-world effectiveness of a diet low in fermentable oligo-, di-, monosaccharides and polyols in irritable bowel syndrome: A systematic review and meta-analysis.. Clin Nutr, 2024.
  5. Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet.. Clin Gastroenterol Hepatol, 2022.
  6. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial.. Lancet Gastroenterol Hepatol, 2024.
  7. Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs.. World J Gastroenterol, 2017.
  8. Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial.. Gut Microbes, 2026.
  9. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis.. Am J Clin Nutr, 2022.
  10. Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: A randomized crossover trial.. Clin Nutr, 2022.
  11. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.. Gastroenterology, 2020.
  12. Effects of a Low FODMAP Diet in Inflammatory Bowel Disease and Patient Experiences: A Mixed Methods Systematic Literature Review and Meta-Analysis.. J Hum Nutr Diet, 2025.
  13. All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome.. Clin Gastroenterol Hepatol, 2025.